India greenlights eight orphan drugs, transforming rare disease treatment

In a major boost to the domestic pharmaceutical industry, the Indian government has approved the manufacture of eight orphan drugs.

These life-saving medications will address critical unmet needs for patients suffering from rare diseases like hereditary tyrosinemia type 1, spinal muscular atrophy, and Lennox-Gastaut syndrome, among others.

The Indian government's Production Linked Incentive (PLI) scheme is gaining traction. With 32 projects successfully completed, the nation is set to significantly enhance its domestic manufacturing capabilities for crucial pharmaceutical components like key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs).